MacroChem CEO will Present at NY Society of Security Analysts' Conference on Investing in Specialty Pharmaceuticals & Biotech, N

Share Name	Share Symbol	Market	Type
Macrochem (MM)	NASDAQ:MCHM	NASDAQ	Common Stock

Share Name

Share Symbol

Market

Type

Macrochem (MM)

NASDAQ:MCHM

NASDAQ

Common Stock

Price Change

% Change

Share Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

MacroChem CEO will Present at NY Society of Security Analysts' Conference on Investing in Specialty Pharmaceuticals & Biotech, N

15/11/2004 2:41pm

PR Newswire (US)

Macrochem (NASDAQ:MCHM)
Historical Stock Chart

From May 2019 to May 2024

MacroChem CEO will Present at NY Society of Security Analysts' Conference on Investing in Specialty Pharmaceuticals & Biotech, November 16 in New York LEXINGTON, Mass., Nov. 15 /PRNewswire-FirstCall/ -- MacroChem Corporation (NasdaqSC: MCHM), a specialty pharmaceutical company, has announced that Robert J. DeLuccia, president and chief executive officer, will review the company's clinical-program status and business strategy at the New York Society of Security Analysts 8th Annual Healthcare Industry Conference: Focus on Investing in Specialty Pharmaceuticals and Biotechnology, to be held November 16 and 17, at The Harvard Club in New York. MacroChem develops topical prescription products based on its patented enhancer technology, SEPA(R). Mr. DeLuccia's presentation, scheduled for November 16 at 10:40 AM, will review MacroChem's specialty pharmaceutical business model and provide an update on the company's two SEPA-enhanced products currently in clinical development -- Opterone(R), a topical testosterone cream for treating male hypogonadism, and EcoNail(TM), an econazole nail lacquer for treating onychomycosis (fungal infection of nails). MacroChem expects to begin a planned bioavailability study of Opterone this quarter. Its current Phase 1 tolerance trial of EcoNail in patients with onychomycosis is fully enrolled, and MacroChem expects trial sites to complete the treatment phase by the end of 2004. This presentation will be webcast by Shareholder.com and can be accessed at the MacroChem web site, http://www.macrochem.com/. The web address of MacroChem's presentation is http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=MCHM&item_id=957527 About MacroChem MacroChem is a specialty pharmaceutical company that innovates, develops and commercializes pharmaceuticals administered in novel ways, to treat important medical conditions. MacroChem is developing two products containing its patented enhancer, SEPA: Opterone(TM), a SEPA-enhanced topical treatment for male hypogonadism; and EcoNail(TM), a SEPA-enhanced antifungal nail lacquer to treat a common and potentially debilitating nail infection known as onychomycosis. With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Bernard Patriacca - VP/CFO (781) 862-4003 Media Contact: Donna LaVoie (LaVoie Group) (781) 596-0200 x103 DATASOURCE: MacroChem Corporation CONTACT: Bernard Patriacca, VP/CFO of MacroChem, +1-781-862-4003; or Donna LaVoie of LaVoie Group, +1-781-596-0200 ext. 103 Web site: http://www.macrochem.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

MCHM Macrochem (MM)